multipl driver beyond copaxon nuvar
upgrad drl outperform under-perform lift tp
concern high market expect
time launch full multipl copaxon nuvar stock
extrem ignor aforement drug
strong us pipelin multipl option valuestherefor upgrad
base us pipelin strongexpect bn sale even without
copaxone/nuvar analysi show drl multipl drug gkuvan
gciprodex gremodulin mn opportun help
base us sale continu grow product concentr risk lower
top drug constitut us sale vs
revlimid npv mn even worst case drl case ahead
activ litig trial start celgen settlement
teva/alvogen allow entri post peak share one-third/single-
digit till worst-cas scenario assum eight gener
enter togeth drl npv still high mn
roce doubl three year drive re-rat drl shown great
execut control cost capital-expenditure togeth high-margin
launch us scale-up em expect ebitda compound-annual-growth-rate
roce doubl tp increas factor
revlimid npv ep increas
valu india profit price-to-earnings em price-to-earnings copaxon
nuvar suboxon price-to-earnings base profit
price-to-earnings risk delay us approv lower india growth china
shift tender market delay nuvar copaxon
multipl option valueschina inject innov drug there
upsid china inject file
outlicens oral psoriasi molecul paid bn
otezla lymphoma molecul bla biosimilar rituximab
valuat metric
chg prev ep
rate under-perform outperform
number share mn
price month
price rel chart measur perform
 bse sensex close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau univers toronto focu chart tabl
figur base us pipelin strong reach bn
even without copaxon nuvar
figur multipl mn drug
us pipelin
figur comfort lower concentr us
figur boost lower sg capital-expenditure
sg sale rh
top us product us sale lh
figur increas drl
net cash posit
figur roce doubl next three year
drive re-rat
figur sotp em account target price
dr reddi laboratori limit dr reddi integr
pharmaceut compani focus provid medicin
pharmaceut servic activ ingredi psai segment
price sep rate under-perform outperform target price analyst
good sold
profit tax
free cash flow firm
net chang cash
scenario revlimid valu market
delay copaxon nuvar lead
de-rat stock
scenario pption valu china
asset priced-in stock re-rat price-to-earnings
price rel chart measur perform bse sensex
close
spot exchang rate
multipl driver beyond copaxon
market concern copaxone/nuvar ignor
stock correct delay copaxon nuvar
analysi suggest base pipelin quit strong sale bn
mn without larg drug drl multipl drug
propofol mn gcubicin/zenatan mn product concentr
risk lower top product us sale vs
revlimid npv mn even worst case
revlimid enter trial stage larg contributor drl
us drug size bn eight gener litig teva alvogen settl
drl case ahead other drl tri invalid method use patent
non-infring polymorph patent celgen settlement teva allow volume-
limit licens mid-single-digit share start increas one-third till
howev peak share alvogen single-digit till npv
mn alreadi factor worst caseeight gener enter togeth
increas control cost capital-expenditure
drl posit surpris strong control cost capital-expenditure better
product bold decis exit commercialis specialti product
result lower sg strong expect increas
till like manag new focu strengthen em franchis china
russia india china particular could strong option valu especi
inject lower competit yet valu china inject opportun
drl still file stage monetis like start file start
roce doubl three year drive re-rat
drl roce high-teen dual hit high price eros
us signific currenc depreci venezuela drl cost control
measur high-margin launch us em scale-up expect ebitda
compound-annual-growth-rate roce doubl help re-rat
stock lift tp factor revlimid npv
ep increas valu india profit price-to-earnings em
price-to-earnings copaxon nuvar suboxon price-to-earnings base profit
price-to-earnings risk delay us approv lower india growth china
market shift gpo model
multipl option valu china inject
outlicens innov drug
there upsid china inject opportun outlicens
psoriasi molecul ctcl molecul biosimilar rituximab
pay bn celgen psoriasi oral drug otezla bn sale
psoriasi drl asset saw encourag result could good option
valu although face competit bm oral drug superior efficaci
data otezla api patent expiri alreadi gener
litig anoth lymphoma drug peak sale could mn
better efficaci current market drug ontak drl file bla
mn sale
drl high
assum eight
gener enter
drl npv still
high mn
us em scale-
drive
increas
roce doubl
bn otezla drl
also encourag
charl martineau univers toronto base pipelin strong
reach bn
copaxon
drug gkuvan
market concern copaxone/nuvar
ignor strong us pipelin
investor focu high copaxon nuvar stock correct
delay analysi suggest base us pipelin strong even
without larg drug drl reach sale bn us
mn key driver limited-competit drug like gkuvan mn
opportun drl gciprodex mn gremodulin mn volum
gain high-margin drug like propofol gcubicin zenatan mn
risk product concentr lower top product constitut
us sale vs
base us pipelin strong provid growth despit
delay copaxon nuvar
cautiou drl far market expect high copaxon
nuvar also market valu drug high multipl price-to-earnings
drug delay like major complet
respons letter nuvar could impli potenti approv year line
copaxon drl earlier indic potenti respons queri
therefor approv could come factor copaxon
nuvar full benefit
howev want highlight overal us pipelin drl still strong
pend anda even without copaxon nuvar drl could reach sale
bn us figur vs mn
figur drl pend anda includ
para iv ftf
figur strong pipelin base portfolio
also expect grow
highlight multipl product pipelin next two year strong
driver high margin
kuvan drl settlement allow launch gkuvan limited-
competit product gener competit like
limit three dmf file product market size larg
mn great opportun drl innov may shift
part market pegvalias approv may us
indic treatment phenylketonuria pku howev given
limit competit opportun still larg mn high
ciprodex ear-drop treatment bacteri ear infect latest im
sale mn annual novarti settlement allow launch
drl also settl see launch happen
anoth mn opportun drl
remodulin use treat high blood pressur lung limited-
competit opportun sandoz ftf launch subsequ
entrant teva drl current tent approv
that reason see drl launch happen launch could
earlier expect drl get approv innov
level remodulin mn drug sandoz entri therefor
four gener remodulin good opportun model annual sale
mn drl
ramp-up recent launch cubicin propofol carboprost etc drl
receiv strong approv past two quarter expect major
growth driven market share ramp-up cubicin propofol
carboprost approv cgt competit gener therapi vigabatrin
vimovo exclus ramp-up isotretinoin drug zenatan
figur product us potenti sale drl
launch expect
launch expect
launch expect
launch expect
launch expect
launch expect
top product
us sale
vs
product concentr us lower
one key reason sharp declin us sale sinc drl high
product concentr top product account us sale
concentr come top product account
sale top product gsuboxoneher expect one entrant
wait approv post product larg stabl gtoprol-
xlwe expect high competit drug alreadi build sale declin
mn mn doxilcurr three-gener market
expect coupl gener player next two year build declin
sale mn mn drl share profit natco
doxil
figur top product concentr us lower
top us product us sale
peak volum share
one-third
alvogen limit
single-digit drl
trial start
worst-cas
scenario eight
gener enter
revlimid bn
sale
market size larg
multipl myeloma
revlimid npv mn even worst
revlimid bn drug us treat multipl myeloma innov
settl teva alvogen litig anoth six gener on-going
drl case ahead other trial start drl mainli tri
invalid method use patent multipl myeloma also non-infring
polymorph patent settlement teva allow volume-limit licens mid-single-
digit market share start increas one-third till howev
alvogen settlement allow peak volum share single-digit till show
analysi even worst case scenario eight gener enter
volum share revlimid npv drl mn
revlimid bn drug us grow
revlimid track annualis sale bn size drug larg
also grow fast revenu wit compound-annual-growth-rate
rate steadi last year indic growth larg led price
increas extens treatment durat nevertheless estim opportun
size larg bn gener enter
revlimid belong class immunomodulatori drug
use treat multipl myeloma cancer plasma cell type white blood cell
bone marrow myelodysplast syndrom caus due disrupt product
healthi blood cell mantl cell lymphoma cancer lymph specif type
white blood cell drug exhibit immunomodulatori action wherein increas killer
cell neutralis harm cancer cell drug exist capsul form
figur revlimid bn drug us
driven price increas longer treatment
restrict distribut programm prevent misus
key characterist drug distribut rem risk evalu
mitig strategi framework drug abil caus sever birth
defect classifi teratogen drug critic drug dispens
pharmaci care monitor control environ celgen innov
develop robust rem set-up drug dispens
polymorph patent hold key determin entri
gener
revlimid protect patent list orang book addit non-list
patent orang book patent broadli classifi protect
polymorph form api method use three approv indic
figur revlimid patent estat polymorph patent expir
method treat prevent manag mantl cell lymphoma
type patent
method use
method use
method treat prevent certain type cancer includ primari
metastat cancer
method use
method use
method use
method use
method use
method use
method use
method use
method use
method use
method use
method treatment multipl myeloma
method treatment follicular lymphoma
method treatment multipl myeloma
method treatment multipl myeloma
method treatment multipl myeloma
method treatment newli diagnos multipl myeloma
method treat non-hodgkin lymphoma
method treat non-hodgkin lymphoma
method treat prevent and/or manag myelodysplast syndrom
method treat myelodysplast syndrom use lenalidomid
method treat myelodysplast syndrom
method reduc level tumor necrosi factor mammal
composit matter
polymorph patent cover form api expir
polymorph abil compound exist differ crystal form exhibit
differ physic chemic properti includ bioavail patent import
sinc innov claim certain form exhibit desir therapeut
effect form claim solid crystallin hemihydr approxim one molecul
water everi two molecul api gener exhibit bioequival
differ form compound obtain non-infring judgment focu
on-going gener litig
method use patent cover key indic valid till
revlimid approv three indic major revenu accru
label multipl myeloma patent protect indic valid till oct-
last valid method use patent expir cover indic
mantl cell lymphoma howev last patent unlik block gener entri
method use
patent non-
infring
gener like carv product indic multipl myeloma
enter market case favour rule primari indic
rem patent expir soon unlik constraint
discuss earlier rem key compon ensur control distribut drug
howev patent expir outcom litig
patent unlik impact litig patent expect
continu beyond expiri rem patent
addit orang book list patent celgen assert claim three non-list
patent gener filer protect polymorph form api
multipl gener filer drl case ahead
activ filer natco alvogen settl
total eight gener litig innov hatch
waxman act natco first file litig start sinc
drl cadila cipla alvogen apotex sun hetero file anda
innov settl natco alvogen litig current activ
trial drl case
start
figur drl litig ahead activ patent litig
class patent
polymorph multipl myeloma method use
myelodysplast syndrom method use
polymorph multipl myeloma method use
polymorph multipl myeloma method use
polymorph multipl myeloma
myelodysplast syndrom method use
polymorph mantl cell lymphoma method
myelodysplast syndrom method use
polymorph multipl myeloma method use
polymorph mantl cell lymphoma method use
multipl myeloma myelodysplast syndrom
method use
differenti settlement term far indic opportun may differ
celgen settl natco alvogen term quit differ term
opportun size natco settlement entitl volume-limit licens mid-single-
digit market share commenc increas nearli one-third market
till unrestrict launch allow howev alvogen
grant volume-limit licens start sometim
increas single-digit percentag market share till nearli one-
third natco unrestrict launch allow probabl
alvogen case still earli stage fifth anda filer celgen thu like
enter differenti settlement term gener depend strength
progress case
drl tri prove non-infring key polymorph patent
drl case progress ahead activ litig second file anda
natco key content drl form api differ
celgen drl assert product amorph form differ
crystallin form claim innov help prove non-infring
trial expect start expert discoveri slate close end
drl litig patent abl get non-
infring rule polymorph patent could suffici market entri
method use patent cover multipl myeloma indic expir
natco argument revolv around polymorph form characterist
prior settlement natco celgen argu certain claim construct relat
polymorph patent form natco object limit claim definit could
work favor prove non-infring rem patent move
court invalid judgment markman hear parti settl matter
trial alvogen settlement earli stage litig much
known key point content howev seek invalid rem
litig earli stage
filer cadila cipla apotex sun hetero still go fact
discoveri earli stage litig trial expect commenc
onward factor one-two year appeal final decis
litig expect henc drl potenti enjoy meaning
durat low competit period case favour rule earli settlement
ptab rule testifi strength method use patent
patent trial appeal board ptab us patent trademark offic turn
request gener initi inter-parti review ipr proceed multipl
method use patent across three indic
figur ptab deni institut review method use patent across three indic
us patent trademark offic
class patent
method treat prevent manag mantl cell lymphoma
method treat myelodysplast syndrom
method treat myelodysplast syndrom
method treat prevent and/or manag myelodysplast syndrom
method treatment multipl myeloma
deni sep
deni feb
deni feb
deni feb
deni
assum eight
gener enter
revlimid worst case add mn npv
given uncertainti around gener entri potenti settlement could
materialis next three-four year factor worst-cas scenario gener
enter market outset post natco launch estim
market size larg bn given growth current run rate
bn assum eight gener launch lead high eros
estim share drl eight player market ebitda margin
still high given larg size drug polymorph patent expiri
expect wave gener enter lead eros lower
ebitda add npv valu per share target price
figur revlimid npv rs per share
revlimid annual project dr reddi
gener
sharpli strong
control cost
capital-expenditure
drl taken bold
decis exit
commercialis
increas control cost
drl posit surpris strong control cost capital-expenditure better product
 drl taken strong decis exit commercialis specialti
product result lower also lower sg
strong expect pick-up next three year like
manag new focu strengthen em franchis china russia india
china particular could strong especi inject competit
limit target price current benefit china drl still process
file inject drug revenu contribut like start
drl alreadi net-cash-posit improv
drl posit surpris strong control cost figur capital-expenditure figur
better product figur drl taken strong decis exit
commercialis specialti product sold derma commercialis
molecul result lower also lower sg sale forc
longer two divis remain pipelin product
possibl drl would look partner could lower
signific benefit gener result drl becom net-cash-
posit balanc sheet fcf-gener pick
figur oper leverag benefit cost
control signific
figur stay lower partner
low er spend
sg sale
sg exclud dep amortis compani data credit suiss estim
charl martineau univers toronto figur capital-expenditure control past three
figur improv made drl net cash
posit
acquisit
nuvar etc
em fastest
grow region drl
account
revenu
higher focu build em franchis
among six focu region growth em market china russia india key
focu area drl salienc proport revenu continu
increas figur drl manag mention will go
inorgan rout india also good deal organ focu build mega
brand launch clinic differenti product india russia
figur increas mix emerg market overal sale
em overal sale
higher china
inject oral
china may provid highest growth sale mn drl plan
file signific file oral inject space china fda
allow fast track approv product alreadi approv us
conduct local bioequival studi china given take year get
approv china may huge growth driver next two year may start
contribut meaning onward price-in china upsid current
market also see transit brand gener model generic-gener
gpo group purchas model lead high price eros expect high price
eros oral drug eros expect high inject
segment howev drl made file inject far china yet
base research drl made follow file china post implement
figur drl increas file rate china oral far though
date file china fda
charl martineau univers toronto drl roce low
vs
expect roce
view stock
expect low
copaxon
nuvar factor
strong us pipelin
roce doubl three year drive
drl roce high-teen dual hit high price eros
us signific currenc depreci venezuela cost control effort high-
margin launch us scale-up em expect ebitda compound-annual-growth-rate
roce doubl help stock re-rat
increas tp factor revlimid npv
ep increas valu india profit price-to-earnings em
price-to-earnings copaxon nuvar suboxon price-to-earnings base profit
price-to-earnings risk delay us approv lower india growth china market
shift gpo model delay nuvar copaxon
upgrad outperform tp
factor delay launch nuvar copaxon still increas
ep includ limit competit drug us name
gkuvan gciprodex gremodulin etc half tp upsid also driven includ
npv revlimid model worst-cas scenario eight gener player
para-iv litig launch togeth even case grevlimid
npv mn current build upsid increas file rate
china oral inject product possibl partner psoriasi
molecul ctcl molecul biosimilar rituximab rituximab
market size us larg bn two approv biosimilar
teva/celltrion
astrazeneca/samsung drl celltrion team expect launch first rituxan
biosimilar
phase
figur sum-of-the-part tp
suboxon valu low er ep
copaxon full upsid
nuvar full upsid
india em expect fastest grow
expect overal sale compound-annual-growth-rate india em portfolio
grow faster expect us sale growth come post due high
base nuvar copaxon therefor drl renew focu em help
sustain high-single-digit sale growth post although sale compound-annual-growth-rate low high-
single-digit ebitda compound-annual-growth-rate strong compound-annual-growth-rate due high-margin launch
us oper leverag benefit em higher product cost
figur india em expect fastest grow
proprietari other
roce doubl next three year
drl roce ex cash post tax high-teen dual hit
us high price eros impact buyer consolid lower venezuela
sale given high currenc depreci cost control effort sale
pick us em roce expect roce doubl
strong launch us continu oper leverag benefit
could posit effect re-rat histor multipl figur
benefit
continu ebitda
compound-annual-growth-rate expect
figur roce doubl next three year
impact high us
price eros
charl martineau univers toronto figur improv roce could drive re-rat stock
industri
eros us
figur drl trade discount peer
delay us approv drl suppli us multipl facil
advers inspect result us fda facil could impact number
launch us
india growth impact trade gener generic-gener drl suppli
mainli brand gener segment india pharma market case volum
shift either trade gener generic-gener pick may like impact growth
indian pharma market also revenu compound-annual-growth-rate assum
larg part china market shift gpo model current china larg
brand gener market part market start shift gpo model
led sharpli lower price molecul transit gpo
model acceler overal margin pharma compani come
china also impact option valu drl china
delay nuvar copaxon us complex drug
case nuvar gener approv yet current
assum launch drug queri us fda
rule case commercialis timelin could delay
bla lymphoma
drug
file also
start china
bn orla psoriasi
china
inject outlicens innov
announc acquisit celgen otezla bn otezla oral
treatment psoriasi bn sale psoriasi indic us
psoriasi market larg current option limit oral space drl
asset also oral treatment psoriasi data encourag
drl look partner could good option valu option valu
though would impact bm ph oral drug show superior efficaci
trial otezla api patent expir alreadi gener
litig anoth lymphoma drug peak sale could
mn better efficaci current market drug ontak drl file
bla
tepilamid fumar belong class fumar acid ester
strong immunosuppress effect drug develop drl oral
treatment moder sever plaqu psoriasi complet phase trial
excit space limit avail oral treatment option larg
bn psoriasi market us current domin biolog
primari oral drug avail today otezla apremilast bn sale psoriasi
indic us drug recent divest bms-celgen amgen
bn
figur us psoriasi market larg bn
primarili domin biolog
figur otezla oral treatment psoriasi
wit steadi ramp-up market
psoriasi indic evaluatepharma
buy-out indic larg potenti oral treatment space
otezla indic treatment moder sever plaqu psoriasi psoriat
arthriti sinc launch wit fast ramp-up biologics-
domin space reach bn sale us psoriasi indic alon amgen
expect grow drug low doubl digit next five year consensu estim
bn sale psoriasi indic denot oral solid treatment
grow fast provid exhibit compar efficaci paramet vs biolog
increas adopt oral expens biolog
trial result diverg otezla efficaci could
higher side-effect
drl announc posit top line result phase studi result
strictli compar paramet measur differ time point indic
good efficaci vi -- vi otezla howev side effect
sever compar otezla come class fumar acid ester
drug advers event report trial lymphocytopenia low white
blood cell count eosinophilia gastro-intestin disord diarrhea nausea
abdomin pain vomit otezla studi report milder advers event
diarrhea nausea vomit absenc quantit data advers event
definit like-to-lik comparison
figur otezla clinic trial result
pasi psoriasi area sever index primari tool measur sever extent psoriasi bid bi die twice day qd
quaqu die day compani data credit suiss research
phase trial drl may like seek partner conduct trial subsequ
commerci launch line approach commercialis proprietari pipelin
asset case phase trial replic phase find option valu larg
drl given otezla success
risk effect bm pipelin drug addit risk otezla
genericis sub-optim phase clinic trial result
key risk face drl compet oral treatment psoriasi exhibit superior
efficaci bm pipelin drug oral treatment moder sever
plaqu psoriasi current undergo phase clinic trial phase result
releas strong supersed drl ahead drl drug
clinic trial progress significantli influenc market format psoriasi oral
treatment drug entri consensu estim alreadi project sale
drug increas sharpli mn us within three year launch
drug sever limit drl gain market
bm product
superior
otezla alreadi
litig gener
drl drug
quaqu altera die everi day compani data credit suiss estim
better
otezla five-year new chemic exclus expir post
slew litig ftf litig includ drl ds patent
expir amneal hetero receiv tent approv well
unlik larg gener opportun potenti impact market share
gain compet oral psoriasi treatment drug like
addit risk phase clinic trial reflect posit data
obtain phase result place drl disadvantag
overal consid larg market size case-in-point otezla success oral
altern biolog treatment option valu pipelin drug
meaning drl also indic expand indic drug cover
relaps form multipl sclerosi larg bn market
us thu provid potenti upsid option valu current
model upsid drl remain option valu
orphan drug lymphoma peak sale could
mn
denileukin diftifox biolog drug treatment cutan t-cell lymphoma
ctcl ctcl rare form cancer occur t-cell normal fight
germ part immun system start attack skin instead act
receptor bind diphtheria toxin enter cell inhibit protein
synthesi multipl us fda approv treatment nearli help
reduc progress rather cure
orphan drug sizabl market
due rare natur condit drug treat ctcl classifi orphan
drug global market size estim mn us
largest market us total incid case expect
grow compound-annual-growth-rate term valu market size us estim
mn present drl decent opportun size given earli entri
market howev given limit growth volum incid case market
growth need driven price
nearli twice bio-act current market ontak
activ agent ontak improv puriti translat
higher bioactiv efficaci ontak current market drug approv
fda full approv indic ctcl grant drug
market eisai drl licens ontak reach peak sale
current gener mn sale annual us given
improv efficaci likelihood gener higher sale ontak
charl martineau univers toronto figur improv version ontak wit higher sale
on-going phase trial bla file
drl current undergo phase trial us expect
complet year guid bla file drl retain right
commercialis global except asia includ japan howev drl hold option
valu develop market drug india
multipl clinic trial on-going lead crowd market
market like wit entri multipl candid space poteligeo
kyowa approv us fda ctcl similarli us fda expand
indic seattl genet adcetri includ ctcl janssen
soligenix pipelin candid phase trial also go
increas competit intens medium long term
compani mention price
